West Pharmaceutical Services

Health Care Health Care Supplies Exton, Pennsylvania Last filing Feb 17, 2026 · FY2025

                    Revenue
                    FY2025
                
$3.1B
                    3y CAGR +2.1%
                    
                    P29
                    
                    n/a
                    
                    Net income
                    FY2025
                
$493.7M
                    Net margin +16.1%
                    
                    P70
                    
                    n/a
                    
                    Total assets
                    FY2025
                
$4.3B
                    ROA +11.6%
                    
                    P78
                    
                    n/a
                    
                    Operating cash flow
                    FY2025
                
$754.8M
                    FCF margin +15.3%
                    
                    P51
                    
                    n/a

18 yrs · FY2008–FY2025 9 filed · 0 derived · 0 blank

1Y 3Y 5Y 10Y

Dollars % of revenue % of assets YoY % CAGR

Each cell as a share of that year’s revenue.

Balance Sheet

Assets, liabilities, and equity

32 accounts · 1 year

Total assets $4.3B

Total liabilities $1.1B

Shareholders equity $3.2B

Account	2025	Trend
Assets
Cash and Cash Equivalents	25.7%
Accounts Receivable	18.7%
Inventory	14.4%
Prepaid Expenses	5.5%
Other Current Assets	5.5%
Total Current Assets	64.4%
Property,Plant and Equipment	56.2%
Operating Lease Assets	3.8%
Goodwill	3.6%
Intangible Assets	0.3%
Deferred Tax Assets	1.2%
Other Noncurrent Assets	2.6%
Total Assets	138.9%
Liabilities
Accounts Payable	8.3%
Accrued Liabilities	0.0%
Current Portion of Long Term Debt	0.0%
Operating Lease Liabilities	0.7%
Other Current Liabilities	7.0%
Total Current Liabilities	21.3%
Long Term Debt	6.6%
Operating Lease Liabilities Noncurrent	3.1%
Deferred Tax Liabilities	0.7%
Other Noncurrent Liabilities	2.4%
Total Liabilities	35.6%
Equity
Preferred Stock	0.0%
Common Stock	0.6%
Additional Paid In Capital	0.0%
Retained Earnings	142.3%
Treasury Stock	36.2%
Accumulated Other Comprehensive Income	-3.4%
Total Stockholders Equity	103.3%
Total Liabilitiesand Equity	138.9%

Income Statement

Revenue, expense, and profitability

19 accounts · 1 year

Revenue $3.1B

Operating income $584.9M

Net income $493.7M

Account	2025	Trend
IncomeStatement
Revenues Total Revenue	100.0%
Expenses Cost of Revenue	64.1%
Expenses Research and Development	2.4%
Expenses Selling,General and Administrative	12.8%
Expenses Depreciation and Amortization	5.6%
Expenses Share Based Compensation	0.8%
Other Income Expense Gross Profit	35.9%
Other Income Expense Operating Income	19.0%
Other Income Expense Interest Income	0.6%
Other Income Expense Interest Expense	0.5%
Other Income Expense Other Income/expense	-0.0%
Other Income Expense Income Before Tax	19.5%
Income Tax Income Tax Expense	4.0%
net Income net Income	16.1%
net Income Comprehensive Income	21.0%
Earnings Per Share Basic Eps	0.0%
Earnings Per Share Diluted Eps	0.0%
Earnings Per Share Weighted Average Shares Basic	2.4%
Earnings Per Share Weighted Average Shares Diluted	2.4%

Cash Flow Statement

Operating, investing, and financing flows

19 accounts · 1 year

Operating cash flow $754.8M

Investing cash flow $-285.9M

Financing cash flow $-185.1M

Account	2025	Trend
CashFlow
Operating Activities net Income	16.1%
Operating Activities Depreciation and Amortization	5.6%
Operating Activities Stock Based Compensation	0.8%
Operating Activities Deferred Income Taxes	-0.4%
Operating Activities Changes In Operating Assets and Liabilities	2.4%
Operating Activities net Cash From Operating Activities	24.6%
Investing Activities Capital Expenditures	9.3%
Investing Activities Other Investing Activities	0.0%
Investing Activities net Cash From Investing Activities	-9.3%
Financing Activities Repayment of Debt	0.0%
Financing Activities Repurchase of Common Stock	4.4%
Financing Activities Dividends Paid	2.0%
Financing Activities Proceeds From Stock Issuance	0.4%
Financing Activities Tax Withholding On Stock Based Compensation	0.1%
Financing Activities net Cash From Financing Activities	-6.0%
Cash Reconciliation Effect of Exchange Rate On Cash	0.7%
Cash Reconciliation net Change In Cash	10.0%
Cash Reconciliation Cash At Beginning of Period	25.7%
Cash Reconciliation Cash At End of Period	25.7%

Key Ratios

Margins, returns, liquidity, leverage, efficiency

Computed at import · 1 year

Ratio	2025
Profitability
Gross margin	+35.9%
Operating margin	+19.0%
Net margin	+16.1%
FCF margin	+15.3%
Growth
Revenue CAGR (3y)	+2.1%
Returns
ROE	+15.5%
ROA	+11.6%
ROIC	+18.0%
Liquidity
Current ratio	3.02x
Quick ratio	2.09x
Leverage
D/E	0.34x
Interest coverage	38.74x
Efficiency
Asset turnover	0.72x
Cash conversion cycle	+103d

Valuation

Price against fundamentals

FY2025 fundamentals · no price

No price data cached, so there is nothing to multiply. Load prices from the Stock Data tab and this panel reprices itself.

Notes

Your annotations

Not watched

West Pharmaceutical Services

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Recent price history